Mitochondrial Cardiomyopathy
Definition
Cardiomyopathy arising from pathogenic variants in mitochondrial genes encoded by either the nuclear genome or the mitochondrial DNA (mtDNA), causing impaired oxidative phosphorylation (OXPHOS). Primary mitochondrial cardiomyopathies typically manifest with atrioventricular conduction defects and abnormal heart muscle structure or function, and may present as hypertrophic, dilated, or restrictive forms.
Key Concepts
Epidemiology
- ~30% of patients with genetically confirmed mitochondrial disorders have cardiovascular involvement. sources/mitochondrial-cv-aha-2025 ★★★★★
- CVD is the most common cause of death among adults with mitochondrial disorders. sources/mitochondrial-cv-aha-2025 ★★★★★
- Cardiomyopathy present in 29–40% of patients; ECG abnormalities in 39–68%. sources/mitochondrial-cv-aha-2025 ★★★★★
- Pediatric survival rate with cardiac involvement is only 18%; adults generally have better prognosis. sources/mitochondrial-cv-aha-2025 ★★★★★
Phenotypes
- HCM is the most common phenotype, may present in the antenatal period; obstructive HCM is rare. sources/mitochondrial-cv-aha-2025 ★★★★★
- HCM may progress to systolic dysfunction and DCM; DCM may arise primarily or secondarily. sources/mitochondrial-cv-aha-2025 ★★★★★
- Restrictive cardiomyopathy is rare in mitochondrial disease. sources/mitochondrial-cv-aha-2025 ★★★★★
- Histiocytoid cardiomyopathy has been reported but is extremely rare; causal link unconfirmed. sources/mitochondrial-cv-aha-2025 ★★★★★
mtDNA Syndromes With Cardiac Manifestations
| Syndrome | Variant(s) | Key Cardiac Features |
|---|---|---|
| MELAS | m.3243A>G (MT-TL1); heteroplasmy 50–80% | HCM most common; DCM, RCM, hypertrabeculation, WPW, SCD |
| MIDD | m.3243A>G (MT-TL1); heteroplasmy 10–40% | HCM, DCM, WPW, AF, sinoatrial node dysfunction |
| MERRF | m.8344A>G (MT-TK); 83–90% of MERRF | DCM, HCM, WPW, SVT, RBBB |
| Kearns-Sayre | Large sporadic mtDNA deletion | Cardiac involvement up to 50%; SCD up to 20% from heart block; LBBB/RBBB, torsades de pointes |
| LHON | m.11778G>A, m.3460G>A, m.14484T>C | HCM, WPW, VT, SCD; mortality doubled |
| Leigh syndrome | >100 genes (mtDNA and nuclear) | HCM most common; DCM, WPW, heart block |
| Pearson syndrome | Large mtDNA deletions (4.9–14 kb) | LVH, LQT, depolarization abnormalities; most deaths by age 3 |
Nuclear-Encoded Mitochondrial Diseases With Cardiac Manifestations (Selected)
| Disease | Gene | Key Cardiac Features |
|---|---|---|
| Barth syndrome | TAFAZZIN (X-linked) | DCM, hypertrabeculation, LQT, WPW, VT, SCD; mean life expectancy 40 y |
| DCMA syndrome | DNAJC19 (AR) | DCM, LQT; most deaths by 15 months |
| Friedreich ataxia | FXN triplet repeat (AR) | HCM, DCM, HF, SVT, AF; mean life expectancy 40 y |
| PPA2 | PPA2 (AR) | SCD/VF triggered by minimal alcohol at any age; extreme alcohol hypersensitivity |
| Complex I deficiency | >30 nuclear genes (AR) | HCM, DCM, Leigh syndrome |
| Complex IV deficiency | COX6B1, SURF1, SCO2 (AR) | DCM, HCM, histiocytoid cardiomyopathy |
| mtDNA depletion (AGK/Sengers) | AGK (AR) | Hypertrophic obstructive cardiomyopathy, SCD |
| NDUFB11 deficiency | NDUFB11 (X-linked) | VF, VT, histiocytoid CMP, DCM, SCD |
Diagnosis
- Most cardiomyopathy and arrhythmia gene panels do not include mitochondrial genes (nuclear or mtDNA). sources/mitochondrial-cv-aha-2025 ★★★★★
- WGS (or WES) is recommended as first-line for suspected mitochondrial disease, not targeted panels. sources/mitochondrial-cv-aha-2025 ★★★★★
- Genetic testing should include comprehensive pretest counselling (emotional, ethical, legal implications); genetic counsellor involvement recommended. sources/mitochondrial-cv-aha-2025 ★★★★★
Cardiac Screening
- Cardiac evaluation at diagnosis: physical exam, ECG, ambulatory ECG, echocardiography or CMR. sources/mitochondrial-cv-aha-2025 ★★★★★
- Periodic screening every 3–5 years recommended for patients with MERRF, MELAS, or MIDD even without cardiac symptoms. sources/mitochondrial-cv-aha-2025 ★★★★★
- CMR provides tissue characterisation and is underutilised; further research needed in this population. sources/mitochondrial-cv-aha-2025 ★★★★★
Management
- Coordinated multidisciplinary care: neurology, cardiology, arrhythmia management, pulmonology, genetics. sources/mitochondrial-cv-aha-2025 ★★★★★
- Conventional HF therapies, pacing, CRT, ICD, and (rarely) heart transplantation are appropriate. sources/mitochondrial-cv-aha-2025 ★★★★★
- No RCT evidence supports targeted mitochondrial interventions over conventional treatment. sources/mitochondrial-cv-aha-2025 ★★★★★
- PPA2 patients must be counselled to abstain from all alcohol. sources/mitochondrial-cv-aha-2025 ★★★★★
Contradictions / Open Questions
- The biochemical threshold VAF required for most pathogenic variants outside tRNA genes is unknown; tRNA variants typically require >60% VAF, but this varies with haplogroup, tissue, and age. sources/mitochondrial-cv-aha-2025 ★★★★★
- Whether histiocytoid cardiomyopathy is causally linked to mitochondrial disease remains unresolved due to extreme rarity. sources/mitochondrial-cv-aha-2025 ★★★★★
- Causal vs. secondary vs. bystander role of specific mtDNA deletions/variants in common CVD is unclear. sources/mitochondrial-cv-aha-2025 ★★★★★
- Whether mtDNA copy number or variant level variation within an individual's own tissues or across individuals is more prognostically relevant is understudied. sources/mitochondrial-cv-aha-2025 ★★★★★
Connections
- Related to concepts/Heteroplasmy — core mechanism governing penetrance of mitochondrial cardiomyopathy
- Related to concepts/Genetic-Testing-in-Cardiomyopathy — WGS vs. panel testing recommendations
- Related to entities/HCM — dominant phenotype in mtDNA disease
- Related to entities/DCM — mitochondrial causes of DCM
- Related to entities/Long-QT-Syndrome — LQT is present in multiple mitochondrial syndromes
- Related to entities/Atrial-Fibrillation — m.3243A>G (MIDD) causes AF; haplogroup associations
- Related to entities/Heart-Failure — leading cause of death in mitochondrial disease